Professor Antoine Andremont - M.D., Ph. D. - Co-founder and President of the Scientific Board

advisors-antoine-andremont.jpgProfessor Antoine ANDREMONT is amongst the leading international experts in the field focused on the consequences of antibiotherapies on the evolution of bacterial resistance and on the occurrence of nosocomial infections. He is the author of over 140 international publications and has filed 5 patents dealing with mechanisms of resistance. Prof. Antoine Andremont is also part of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) and the EU Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) as an expert and a scientific advisor.
Primarily trained as a pediatrician and microbiologist, both in France and in the USA, he acted as medical microbiologist at the Institut Gustave Roussy, moved as Professor at the School of Pharmacy of University of Paris XI, and then joined University of Paris VII Denis Diderot Medical school and still leads there a research group focusing on the emergence of bacterial resistance in the commensal flora. At the medical level, Prof. Antoine Andremont heads the clinical bacteriology laboratory of the Bichat-Claude Bernard Hospital in Paris, being confronted daily with the continuous rise in bacterial resistance and the consecutive difficulties to treat infected patients.
Co-founder of Da Volterra, the expertise of Prof. Andremont, with a long tradition in the evaluation of innovative treatments of infectious diseases, is a major success factor of the company products positioning and development strategies towards patient needs.

Doctor Frédéric Barbut - Pharm.D., Ph.D.

Doctor Frédéric Barbut is at the Head of the Infection Control Unit & Head of the National Reference Laboratory for Clostridium difficile, AP-HP Saint-Antoine hospital, Paris, France. His research activity is focused on Clostridium difficile infections.

Professor Alain Bousquet-Mélou - Vet.D., Ph.D.

Professor Alain Bousquet-Mélou is accompanying Da Volterra in the design of the animal health developments. He teaches pharmacology at the Veterinary School and Faculty of Pharmacy of Toulouse. Member of the Research Center in Food Toxicology, he is the head of the team “Pharmacokinetics, Pharmacodynamics & Modelling” (Toxalim E7). His current research activity is focused on antimicrobial resistance in response to antibiotic use in animals.

Professor Yehuda Carmeli - M.D., Ph.D.

Professor Yehuda Carmeli is the chief of the Division of Epidemiology, National Center for Antibiotic Resistance, and a Senior Staff physician in the Division of Infectious Diseases at the Tel Aviv Medical Center. He is also on the research staff at the Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Professor Jennifer Dressman - Ph.D.

Professor Jennifer Dressman is teaching Pharmaceutical Technology at J.W. Goethe University in Frankfurt, Germany. She is expert in predictive models for the delivery of drugs via the gastrointestinal tract. Specialist in gastroenterological physiology and drug delivery/absorption in the GI tract, Prof. Dressman advises Da Volterra on the development and testing of colonic drug delivery systems.

Professor Bruno Fantin - M.D., Ph.D.

Professor Bruno Fantin is Professor of Internal medicine at University of Paris VII Denis Diderot Medical school; he is a renowned expert of the relationships between PK/PD properties of antibiotics and emergence of bacterial resistance.

Doctor Dale N. Gerding - M.D.

Doctor Dale N. Gerding is an infectious diseases specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America and past chairman of the antibiotic resistance committee of SHEA.  He is a fellow of the Infectious Diseases Society of America and Chair of the National and Global Public Health Committee of IDSA.  He is a fellow of the American College of Physicians and a member of the American Society for Microbiology. 

Professor Stephan Harbarth - M.D.

Professor Stephan Harbarth, Chief of the Prevention Unit for Nosocomial Infections of the Geneva Hospital, is a distinguished infectious diseases specialist and hospital epidemiologist who has published more than 40 original articles in peer-reviewed journals.

Professor Stuart B. Levy - M.D., Ph.D.

Professor Stuart B. Levy is a pioneer and world-renowned expert in the field of antibiotic resistance. Director of the Center for Adaptation Genetics and Drug Resistance at Tufts University School of Medicine, he has over 30 years of research experience on the mechanisms of microbial drug resistance;  he is co-founder and Chief Scientific Officer of Paratek Pharmaceuticals.

Doctor Eve Slater - M.D., F.A.C.C.

Dr. Eve E. Slater served as an Assistant Secretary for Health (ASH) of the US Department of Health and Human Services from January 2002 to February 2003 and served as the Chief Health Policy Advisor to Secretary Tommy Thompson and Acting Assistant Secretary for Health at US Department of Health and Human Services from 2001 to 2002. Dr. Slater has extensive experience in the pharmaceutical industry, including 19 years in Senior Management at Merck Research Laboratories.

Professor Mark Wilcox - Ph.D.

Professor Mark Wilcox is the Lead on Clostridium difficile for the Public Health England (PHE). He is a Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds (Leeds Institute of Molecular Medicine). He has formerly been the Director of Infection Prevention (4 years), Infection Control Doctor (8 years) and Clinical Director of Pathology (6 years) at LTHT.